Rolf W Sparidans

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Topics

Tandem Mass Spectrometry

Tyrosine Kinase

Advanced Non Small Cell Lung Cancer

Top Venues

Pharmaceuticals (Basel, Switzerland)

Biomedical chromatography : BMC

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Irene A Retmana, Nancy H C Loos, Alfred H Schinkel, Jos H Beijnen, Rolf W Sparidans
Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices. Biomedical chromatography : BMC (2023)
Jing Wang, M Merve Susam, Changpei Gan, Rolf W Sparidans, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure. Pharmaceuticals (Basel, Switzerland) 15 (9) (2022)
M Merve Susam, Jing Wang, Alfred H Schinkel, Jos H Beijnen, Rolf W Sparidans
Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Biomedical chromatography : BMC 36 (11) (2022)
Yaogeng Wang, Rolf W Sparidans, Sander Potters, Rahime Şentürk, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO). Pharmaceuticals (Basel, Switzerland) 14 (11) (2021)
Johannes J M Rood, Amer Jamalpoor, Stéphanie van Hoppe, Matthijs J van Haren, Roeland E Wasmann, Manoe J Janssen, Alfred H Schinkel, Rosalinde Masereeuw, Jos H Beijnen, Rolf W Sparidans
Extrahepatic metabolism of ibrutinib. Investigational new drugs 39 (1) (2020)